Dimitar Efremov

Dr. Dimitar Efremov

Molecular Hematology, International Centre for Genetic Engineering & Biotechnology (ICGEB), Padriciano, Trieste, Italy
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2004 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BMBradley T. Messmer
Bradley T. Messmer
EAEmilia Albesiano
Emilia Albesiano
Dimitar EfremovDimitar Efremov
Dimitar Efremov
FGFabio Ghiotto
Fabio Ghiotto
SASteven Allen
Steven Allen
NCNicholas Chiorazzi
Nicholas Chiorazzi
Notch signaling has been shown to play a pivotal role in inducing T lineage commitment. However, T cell progenitors are known to retain other lineage potential long after the first point at which Notch signaling is required. Thus, additional requirements for Notch signals and the timing of these events relative to intrathymic differentiation remain unknown. Here, we address this issue by culturing subsets of CD4 CD8 double negative (DN) thymocytes on control stromal cells or stromal cells expressing Delta-like 1 (Dll1). All DN subsets were found to require Notch signals to differentiate into CD4+ CD8+ T cells. Using clonal analyses, we show that CD44+ CD25+ (DN2) cells, which appeared committed to the T cell lineage when cultured on Dll1-expressing stromal cells, nonetheless gave rise to natural killer cells with a progenitor frequency similar to that of CD44+ CD25− (DN1) thymocytes when Notch signaling was absent. These data, together with the observation that Dll1 is expressed on stromal cells throughout the thymic cortex, indicates that Notch receptor–ligand interactions are necessary for induction and maintenance of T cell lineage specification at both the DN1 and DN2 stages of T cell development, suggesting that the Notch-induced repression of the B cell fate is temporally separate from Notch-induced commitment to the T lineage.

15 January 2008 in Blood
Verified
Journal Article
Closed access
PDF file
PLPablo G. Longo
Pablo G. Longo
LLLuca Laurenti
Luca Laurenti
SGStefania Gobessi
Stefania Gobessi
SSSimona Sica
Simona Sica
GLGiuseppe Leone
Giuseppe Leone
Dimitar EfremovDimitar Efremov
Dimitar Efremov
Sustained engagement of the B-cell receptor (BCR) increases apoptosis resistance in chronic lymphocytic leukemia (CLL) B cells, whereas transient stimulation usually has an opposite effect. The antiapoptotic BCR signal has been associated with prolonged activation of the PI3K/Akt and MEK/ERK pathways, which are key regulators of survival and proliferation in various cell types. To further define the relative contribution of the Akt and ERK kinases in regulating CLL B-cell survival, we introduced constitutively active mutants of Akt and MEK in primary CLL B cells and evaluated changes in the expression of relevant pro- and antiapoptotic proteins. Sustained activation of Akt resulted in increased leukemic cell viability and increased expression of the antiapoptotic proteins Mcl-1, Bcl-xL, and X-linked inhibitor of apoptosis protein (XIAP), thus largely recapitulating the effects of sustained BCR stimulation. Constitutively active MEK2 also up-regulated XIAP, but did not show a significant impact on leukemic cell survival. Down-regulation of Mcl-1 by siRNA treatment induced rapid and potent apoptosis in CLL B cells and blocked the antiapoptotic effect of sustained BCR stimulation, whereas down-regulation of Bcl-xL and XIAP did not affect leukemic cell viability. These data demonstrate that Akt and Mcl-1 are major components of a survival pathway that can be activated in CLL B cells by antigen stimulation.

15 June 2005 in Blood
Verified
Journal Article
Closed access
PDF file
APAleksandar Petlickovski
Aleksandar Petlickovski
LLLuca Laurenti
Luca Laurenti
XLXiaoping Li
Xiaoping Li
SMSara Marietti
Sara Marietti
PCPatrizia Chiusolo
Patrizia Chiusolo
Dimitar EfremovDimitar Efremov
Dimitar Efremov
The clinical course of chronic lymphocytic leukemia (CLL) differs significantly between patients with mutated (M-CLL) and unmutated (U-CLL) immunoglobulin (Ig) variable heavy-chain (VH) genes, implying a role for B-cell receptor (BCR) signaling in the pathogenesis of this disease. We have now investigated activation of downstream BCR signaling pathways in U-CLL and M-CLL B cells using soluble anti-IgM (sol-IgM) and immobilized anti-IgM (imm-IgM) antibodies as models for antigenic stimulation. Ligation of the BCR with sol-IgM induced incomplete responses in both CLL subsets, resembling the pattern described for tolerant B cells. This response was characterized by transient phosphorylation of extracellular signal-related kinase (ERK) and Akt (protein kinase B [PKB]), lack of activation of c-JUN NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK), and variable activation of phospholipase Cγ2 (PLCγ2) and nuclear factor-κB (NF-κB). Stimulation with imm-IgM elicited a more complete BCR signal and significantly prolonged phosphorylation of ERK and Akt, indicating persistent or repetitive BCR signaling. Moreover, this type of stimulation increased the levels of the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1) and protected from chemotherapy-induced apoptosis, whereas induction of apoptosis and down-regulation of Mcl-1 was observed following stimulation with sol-IgM. These data demonstrate that only sustained BCR signaling can promote survival of CLL B cells and indicate that the main difference between CLL with mutated and unmutated VH genes may reside in the availability of such stimulation. (Blood. 2005;105:4820-4827)

20 February 2014 in Blood
Verified
Journal Article
Open access
PDF file
JWJennifer A. Woyach
Jennifer A. Woyach
EBEngin Bojnik
Engin Bojnik
ARAmy S. Ruppert
Amy S. Ruppert
MSMatthew R. Stefanovski
Matthew R. Stefanovski
VGVirginia M. Goettl
Virginia M. Goettl
AJAmy J. Johnson
Amy J. Johnson
Key Points: Kinase-functional BTK is important in the development and expansion of CLL. Both targeted genetic inactivation of BTK and inhibition of BTK by ibrutinib inhibit the development of CLL in the TCL1 mouse model.

18 December 2008 in Leukemia
Verified
Journal Article
Closed access
PDF file
SGS Gobessi
S Gobessi
LLL Laurenti
L Laurenti
PLP G Longo
P G Longo
LCL Carsetti
L Carsetti
VBV Berno
V Berno
Dimitar EfremovDimitar Efremov
Dimitar Efremov

12 October 2006 in Blood
Verified
Journal Article
Closed access
PDF file
SGStefania Gobessi
Stefania Gobessi
LLLuca Laurenti
Luca Laurenti
PLPablo G. Longo
Pablo G. Longo
SSSimona Sica
Simona Sica
GLGiuseppe Leone
Giuseppe Leone
Dimitar EfremovDimitar Efremov
Dimitar Efremov
Expression of ZAP-70 is an important negative prognostic factor in chronic lymphocytic leukemia (CLL). This protein tyrosine kinase is a key mediator of T-cell receptor (TCR) signaling and is structurally homologous to Syk, which plays an analogous role in B-cell receptor (BCR) signaling. Recent studies indicate that ZAP-70 may participate in BCR signaling as well, but the mechanism of action is not completely understood. We have now compared antigen receptor-induced activation of ZAP-70 in B cells and T cells by analyzing phosphorylation of critical regulatory tyrosine residues. We show that BCR-mediated activation of ZAP-70 is very inefficient in CLL and lymphoma B cells and is negligible when compared to activation of Syk. Despite the inefficient catalytic activation, the ability of ZAP-70 to recruit downstream signaling molecules in response to antigen receptor stimulation appeared relatively preserved. Moreover, ectopic expression of ZAP-70 enhanced and prolonged activation of several key mediators of BCR signaling, such as the Syk, ERK, and Akt kinases, and decreased the rate of ligand-mediated BCR internalization. We conclude that the role of ZAP-70 in BCR signaling is quite distinct from its role in TCR signaling and is likely mediated by inhibition of events that terminate the signaling response.